7:00 AM
 | 
Apr 11, 2019
 |  BC Extra  |  Financial News

TPG, Vida back Asklepios in $235M round

TPG Capital and Vida Ventures have again teamed up to invest in a biotech's megaround, pouring a combined $225 million into gene therapy company Asklepios in exchange for a undisclosed minority stake. The company's founders and board members added another $10 million.

Founded in 2001 and spun out of the Gene Therapy Center at the University of North Carolina-Chapel Hill, Asklepios BioPharmaceutical Inc. (Chapel Hill, N.C.), also known as AskBio, is developing a pipeline of gene therapies for neuromuscular, CNS and...

Read the full 383 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >